{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000520","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.546353+00:00","generated_at":"2026-06-20T18:04:44.200111+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta promotes David R. Shook, M.D., to Chief Medical Officer","bullets":["Dr. Shook joined Nkarta in 2020 and was appointed VP, Clinical Development in 2022.","He has extensive cell therapy development experience, including first-in-human trials with CD19 CAR-NK cells.","Dr. Shook co-developed the membrane-bound IL-15 component of Nkarta’s NK cell platform.","He continues as a practicing pediatric oncologist and transplant physician.","Prior Nkarta, he was at St. Jude Children’s Research Hospital in the lab of scientific founder Dario Campana."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000520","json":"https://secwatch.observer/filing/0000950170-23-000520.json","markdown":"https://secwatch.observer/filing/0000950170-23-000520.md","text":"https://secwatch.observer/filing/0000950170-23-000520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023000520/0000950170-23-000520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023000520/nktx-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:04:44.200111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}